Menu
Osteoarthritis (OA) is the most common form of arthritis and the single most common cause of pain and physical disability in older adults. An estimated 10% to 15% of all adults aged over 60 have some degree of OA, with prevalence being higher among women than men and likely representing underreporting which is common in many disease prevalence studies. Despite the growing OA epidemic and major socio-economic impact, the population is facing a staggering lack of disease-modifying therapies that can bring symptomatic relief and preserve joint function by preventing cartilage- and joint degeneration and thus delaying OA progression. The research specifically aimed at OA management in Europe is scattered and not strategically coordinated, although several networks have OA partly in focus, its minor part of their agenda end lacks the focus and dedicated commitment to coordinate progress. The COST Action will allow us to start the process of building such a European Society, with the aim of coordinating and stimulating more interdisciplinary and transdisciplinary research, technological development and translation of the results to the clinic, aimed at improving the quality of life of those affected by OA in Europe.
Working Group member of CECAV: Bruno Colaço (WG2)
Period: October 2022 to October 2026.
